Mdxhealth Reports Second Quarter 2026 Financial Results
MDxHealth reported Q2 revenue of $27.2 million, up 16% year-over-year, and reaffirmed its 2026 revenue guidance of $110-115 million despite a widening net loss to $9.5 million driven by ExoDx integration costs. The company completed the wind-down of its Resolve mdx business, with subsidiary Delta Laboratories executing an Assignment for the Benefit of Creditors to address liabilities, including a $10.4 million recoupment claim from Novitas Solutions.
Key figures
- Revenue
- $27.2 million
- Guidance
- 2026 revenue $110-115 million
- Revenue Yoy
- 16%
- Deal Value Usd
- 20000000
- Offering Price
- 0.454
- Shares Offered
- 44052862
- Cash balance
- 19200000
- Pro forma cash
- 39200000
- Liquid test volume
- 13578
- Tissue test volume
- 12525
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.